Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [11C]-GSK2256098 500 MBq
GSK2256098 500 MBq · 1 trial · 1 indication
The PET scan was acquired to measure the uptake of radiolabeled GSK2256098 in the heart and lungs, assessed as the volume of distribution (VT). The analysis was performed on Safety Population which comprised of all participants who received a microdose of study treatment.
The PET scan was acquired to measure the uptake of radiolabeled GSK2256098 in the heart and lungs, assessed as the mean standardized uptake value (SUV) averaged over the 60 minute period between 30 and 90 minutes. The analysis was performed on Safety Population which comprised of all participants who received a microdose of study treatment.
| Arm | Type | Description |
|---|---|---|
| [11C]-GSK2256098 | EXPERIMENTAL | Subjects will receive single IV bolus injection of \[11C\]-GSK2256098 over about 30 seconds. Each unit dose will contain up to 500 millibecquerel (MBq) of \[11C\]-GSK2256098 with maximum \[11C\]-GSK2256098 mass \<=10 microgram (mcg). |
| Name | Type | Description |
|---|---|---|
| [11C]-GSK2256098 500 MBq | DRUG | \[11C\]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline. |
Inclusion Criteria: Inclusion criteria for healthy volunteers \- Healthy subjects enrolled between 40 to 70 years inclusive at the time of signing the informed consent. Healthy subjects will be recruited to be age (+/-5 years) and gender matched to idiopathic PAH patients. * Healthy as determined...
GSK2256098 500 MBq is a radiolabeled small molecule developed by GSK plc as a positron emission tomography (PET) imaging agent. It is studied in pulmonary hypertension, including idiopathic pulmonary arterial hypertension (PAH), to evaluate how the tracer distributes in the body. It is an investigational agent in Phase 1 testing.
GSK2256098 500 MBq targets PTK2, also known as focal adhesion kinase (FAK). It is a PTK2 inhibitor, and the carbon-11 radiolabel allows PET imaging to visualize PTK2 expression and tracer biodistribution in the lungs and other tissues.
GSK2256098 500 MBq is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the PET imaging study evaluating this radiolabeled compound in healthy subjects and patients with idiopathic pulmonary arterial hypertension.
GSK2256098 500 MBq is in Phase 1 development. It is an investigational imaging agent and has not been approved for commercial use. The single Phase 1 trial has been completed, and no active trials are currently listed.
GSK2256098 500 MBq was studied in NCT02551653, a Phase 1 PET biodistribution study in healthy subjects and idiopathic pulmonary arterial hypertension patients. The trial enrolled 10 participants in the United Kingdom, included adults aged 40 years and older, and has been completed.
Yes, GSK2256098 500 MBq is also known as [11C]-GSK2256098 500 MBq. The [11C] prefix indicates the compound is labeled with carbon-11, a positron-emitting isotope used for PET imaging. Both names refer to the same radiolabeled imaging agent.